Evaluation of pegylated interferon-α therapy efficacy in patients with inactive hepatitis B surface antigen carrier state

These findings suggest that PegIFNα-2b therapy may offer therapeutic benefits in IHC patients, particularly those with lower baseline HBsAg levels, and should be considered as part of a broader strategy for HBV management.